You are here

Celgene

Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts

Drumbeat of bad news continues at OncoMed as Celgene dumps option on one of its last pipeline efforts

Endpoints

Flag link:

Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory

Why bluebird and Celgene Should Worry About Amgen's Latest Clinical Victory

Motley Fool

Flag link:

Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete

Celgene's CEO Wants to Make the Biotech's Best-Selling Drug Obsolete

Motley Fool

Flag link:

The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate

The reinvention of Bob Hugin: Amid anger over drug prices, a former pharma CEO makes a run for the Senate

Stat

Flag link:

Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review

Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review

Yahoo/Zacks.com

Bristol-Myers Squibb

Multiple Myeloma

Flag link:

Can Celgene’s Most Important Drugs Keep Growing?

Can Celgene’s Most Important Drugs Keep Growing?

Motley Fool

Multiple Myeloma

Flag link:

Celgene (CELG) Beats on Q2 Earnings, Ups View

Celgene (CELG) Beats on Q2 Earnings, Ups View

Marketwatch

Flag link:

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

BeiGene Initiates Ph III Trial of PD-1 Inhibitor Tislelizumab + Chemotherapy in Advanced Non-Squamous Non-Small Cell Lung Cancer in China

CP Wire

monoclonal antibodies

Flag link:

Can Celgene's latest Revlimid win reverse the company's bad-news streak?

Can Celgene's latest Revlimid win reverse the company's bad-news streak?

Fierce Pharma

clinical trials

non-Hodgkin lymphoma

Flag link:

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

Number 7? Celgene partner BeiGene joins the crowd with stellar PD-1/L1 data from a pivotal test

Endpoints

Hodgkin's lymphoma

Flag link:

7 companies to watch during Q2 earnings

7 companies to watch during Q2 earnings

Biopharma Dive

Gilead Sciences

Spark Therapeutics

Flag link:

Novartis' MS patent win also a win for Celgene's impending MS drug: analyst

Novartis' MS patent win also a win for Celgene's impending MS drug: analyst

Medical Marketing and Media

multiple sclerosis

Flag link:

Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology

Takeda, Celgene Invest $6 Million in Presage Biosciences Cancer Testing Technology

BioSpace

Presage Biosciences

Flag link:

Many Drugmakers Ignore Trump—and Raise Prices Anyway

Many Drugmakers Ignore Trump—and Raise Prices Anyway

Bloomberg

Flag link:

MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too

MS patent win boosts Novartis’ Gilenya, helps Celgene and maybe Biogen too

Fierce Pharma

Flag link:

Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Celgene tweaks trial of myeloma CAR-T bb2121, raising dose

Fierce Biotech

clinical trials

Multiple Myeloma

Flag link:

With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?

With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?

Fierce Pharma

Flag link:

A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

A 7-year-old alliance between Celgene and Acceleron is paying off with more promising PhIII data for luspatercept

Endpoints

beta thalassemia

Flag link:

More than $100 Billion Spent on M&A in the First 6 Months of 2018

More than $100 Billion Spent on M&A in the First 6 Months of 2018

BioSpace

Impact Biomedicines

Flag link:

3 Best Biotech Acquisitions of 2018 (So Far)

3 Best Biotech Acquisitions of 2018 (So Far)

Motley Fool

Juno Therapeutics

Foundation Medicine

Flag link:

Pages